Category: Industry News

Positive phase III data for Neurocrine’s Ingrezza in Huntington’s disease

Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…

WFNR celebrates 25th anniversary

“Congratulations to the WFNR for all that it has achieved over the last 25 years.  Today the WFNR is a true advocate for neurorehabilitation” said Professor David Good, WFNR President as the organisation celebrates its 25th anniversary.  He continued: “We’re extremely grateful to all our members who have contributed to the success of the organisation…

ACT Myself -supporting mental health in MS

Biogen launches ACT Myself – a free digital self-help tool to support the mental health of people living with multiple sclerosis (MS) as NHS highlights rise in anxiety among patients Biogen has launched a free, new, digital self-help tool to help people living with multiple sclerosis (MS) navigate the emotional challenges of life with the…